Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Dupixent Wins EU Recommendation for Treating Children 2–11 with Chronic Urticaria

Dupixent’s new EU pediatric CSU indication, backed by LIBERTY‑CUPID trials, promises first‑of‑its‑kind targeted relief for 2‑11‑year‑olds, boosting Regeneron’s market reach and patient care.

Dr. Michael Chen

28/02/2026, 11:28

3 minutes to read

Amgen Shares Steady as New Biologics Show Early Success – Investors Eye Phase 3 Outlook

Amgen’s steady share price, backed by solid earnings and promising biotech pipeline, shows potential upside as Phase 3 data for AMG 301, AMG 701, and AMG 510 emerge.

Dr. Michael Chen

28/02/2026, 08:20

5 minutes to read

Sanofi Wins FDA Approval for Dupixent as First Treatment for Allergic Fungal Rhinosinusitis

Sanofi’s FDA approval of Dupixent for allergic fungal rhinosinusitis shows the drug’s IL‑4/IL‑13 blockade reduces nasal symptoms, steroid use and surgery—boosting its portfolio and investor confidence.

Dr. Michael Chen

25/02/2026, 14:02

5 minutes to read

How Bayer’s Nubeqa vs. Erleada Lawsuit and Glyphosate Supreme Court Appeal Affect Investors and Markets

Explore how Bayer’s lawsuits over Nubeqa vs. Erleada and glyphosate reshape its pharma and crop‑science futures, affecting pricing, regulation, and stock value.

Dr. Michael Chen

24/02/2026, 12:36

5 minutes to read

Novo Nordisk Shares Fall as Obesity Drug Trial Misses Expectations

New data show Novo Nordisk’s NVS‑Obes‑1 failed to beat semaglutide in weight‑loss, causing a sharp share drop, but the company remains focused on diabetes and next‑gen GLP‑1 therapies.

Dr. Michael Chen

24/02/2026, 10:47

4 minutes to read

Qiagen NV’s Overweight Upgrade and New Whole‑Transcriptome Kit Drive Investor Excitement

Qiagen NV’s upcoming whole‑transcriptome kit offers faster, high‑sensitivity RNA‑seq and single‑cell capability, boosting precision diagnostics and investor confidence.

Dr. Michael Chen

22/02/2026, 10:51

5 minutes to read

Roche Advances Breast‑Cancer Therapy with FDA‑Approved RO‑101 and Future ER‑OAR Everolimus Combo

Roche’s FDA‑approved breast‑cancer therapy RO‑101 shows a 12.6‑month median PFS, while its ER‑OAR+everolimus combo promises 9.2‑month PFS and higher response rates—2026‑decision outlook revealed.

Dr. Michael Chen

21/02/2026, 15:43

3 minutes to read

Teva’s Double‑Digit Earnings Outlook Boosted by Patent Win, GS Forecasts 2026 Growth

Teva Pharmaceutical Industries Ltd. is poised for double‑digit earnings growth through 2026, boosted by a strong pipeline of branded generics, specialty drugs, and a winning patent ruling that secures market exclusivity in the β‑catenin oncology spa…

Dr. Michael Chen

21/02/2026, 14:54

5 minutes to read

Insmed Q4 2025 Results: Brinsupri Drives Growth, 2026 Revenue Forecast

Insmed Inc. reports Q4 2025 earnings, highlights Brinsupri’s breakthrough 52‑week efficacy in PNH, and outlines a $30‑$35 M 2026 revenue target.

Dr. Michael Chen

21/02/2026, 00:08

5 minutes to read

Haleon PLC Drives Share Gains With Evidence‑Based Heart Health Supplements

Haleon PLC’s steady rise in a booming cardiovascular‑health supplement market: evidence‑based trials, regulatory alignment, and investor upside.

Dr. Michael Chen

16/02/2026, 04:51

4 minutes to read

Newer articles